TOPICAL COMBINATION IMPROVING THE SIGNS AND SYMPTOMS OF
PLAQUE PSORIASIS IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE
PSORIASIS FORMULATED WITH PROPRIETARY
PRISMATREX™ TECHNOLOGY
i
LAVAL, QC, June 11, 2020 /CNW Telbec/ - Bausch Health,
Canada, which is part of Bausch
Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health"
or the "Company") has announced that Health Canada has
approved the use of DUOBRIITM (0.01% w/w halobetasol
propionate and 0.045% w/w tazarotene) lotion, a topical
prescription medicine indicated for improving the signs and
symptoms of plaque psoriasis in adult patients with moderate to
severe plaque psoriasis.i
A chronic inflammatory condition affecting the regeneration of
skin cells, psoriasis affects its patients not just physically, but
also emotionallyii. Studies suggest that about one
million Canadians are impacted by this skin disease, with 90% of
those affected suffering from plaque psoriasis.ii
DUOBRII is the first and only complementary retinoid-steroid
combination of two ingredients – halobetasol propionate, which
helps with the inflammation associated with psoriasis; and
tazarotene helps with the normal growth of skin cells and by
reducing inflammation.i DUOBRII is formulated with a
unique and proprietary technology called Prismatrex, a polymeric
emulsification system which provides a stable condition of the
product where emulsion droplets retain their distribution across
time and temperature.iii
"With Health Canada's approval of DUOBRII, patients suffering
from plaque psoriasis will soon have an innovative topical
treatment option that uniquely combines two well-known ingredients,
halobetasol propionate and tazarotene with established safety
profiles, into a single lotion offering the complementary benefits
of a retinoid with a steroid for the first line treatment of
moderate to severe psoriasis," said Richard Lajoie, President
and General Manager, Bausch Health,
Canada. "Since psoriasis is a
chronic skin disease, patients require continuous treatment in
order to achieve optimal control of their symptoms. Now, with
DUOBRII, Canadian health care professionals and their patients have
a new topical treatment option that can help achieve those
long-term goals. We remain committed to bringing forward new
medicines, like DUOBRII to meet the varying treatment needs of
patients with psoriasis."
Psoriasis is a difficult condition to treat," said Dr.
Neil H. Shear, MD, FRCPC, Professor
and Head of Dermatology, Sunnybrook Health Sciences Centre.
"Because psoriasis typically appears on visible parts of the body,
it has a significant effect on how my patients feel and interact
with others. Without question, achieving clear skin is the goal of
patients and physicians alike. DUOBRII, which combines a
corticosteroid and a retinoid, is the first new topical treatment
option for psoriasis in many years, with encouraging results that
can be seen in as early as two weeks. As well, it is the only
topical treatment that provides extended clearance
post-treatment."
Clinical trials and studies demonstrated that DUOBRII was
statistically significantly more effective than Vehicle Lotion in
achieving treatment success in the IGA at Week 8, defined as at
least a 2-grade improvement from Baseline and a score of Clear or
Almost Clear in the studies.i According to Dr. Shear,
while other products containing steroids used for treating
psoriasis have a limit to the length of time for their usage,
DUOBRII has no treatment duration limitation. "Patients can
use it until their skin is clear and can re-initiate treatment as
needed."
"Having access to a new, first-line topical treatment is an
important advance for patients with plaque psoriasis," said
Rachael Manion of the Canadian
Association of Psoriasis Patients (CAPP). "The psoriasis community
welcomes the addition of this new once-daily topical treatment
optioniv to the psoriasis treatment toolkit,
especially in light of reduced treatment options for some people
living with psoriasis during the COVID-19 pandemic."
It is expected that DUOBRII will be commercially available
in Canada in late summer 2020.
DUOBRII is manufactured for US and Canadian patients at Bausch
Health's Laval, Quebec
manufacturing facility.
About Bausch Health Companies Inc.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global
company whose mission is to improve people's lives with our health
care products. We develop, manufacture and market a range of
pharmaceutical, medical device and over-the-counter products,
primarily in the therapeutic areas of eye health, gastroenterology
and dermatology. We are delivering on our commitments as we build
an innovative company dedicated to advancing global health.
In Canada, the Company's prescription product portfolio is
focused on eye health, dermatology and cardio-metabolic conditions.
More information can be found on the Company's website
at bauschhealth.ca.
References:
|
|
i DUOBRIITM Product
Monograph. Bausch Health, Canada Inc. June 8, 2020
ii https://www.canadianpsoriasisnetwork.com/wp-content/uploads/2018/09/JTSFinal-r.pdf
iii Data in Health Canada NDS submission
iv Comment is in reference to inconsistent
availability to phototherapy during COVID-19 pandemic. Canadian
Skin Patient Alliance website:
https://canadianskin.ca/education/covid-19#i-am-receiving-phototherapy-for-my-skin-disease-are-dermatologists-continuing-to-offer-these-treatments-in-their-clinics
|
SOURCE Bausch Health